|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32.00 TWD | 0.00% |
|
+3.23% | -8.31% |
Company Valuation: DIVA Laboratories, Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 1,455 | 1,572 | 2,379 | 2,159 | 2,244 | 2,048 |
| Change | - | 8.06% | 51.31% | -9.25% | 3.94% | -8.76% |
| Enterprise Value (EV) 1 | 1,128 | 1,273 | 2,033 | 1,630 | 1,660 | 1,556 |
| Change | - | 12.91% | 59.64% | -19.84% | 1.86% | -6.24% |
| P/E | 95.4x | 72.4x | 48.3x | 29.4x | 24.1x | 22.7x |
| PBR | 1.47x | 1.59x | 2.34x | 2.09x | 2.13x | 1.99x |
| PEG | - | 1.7x | 0x | 0.6x | 0.9x | -7.22x |
| Capitalization / Revenue | 1.97x | 2.21x | 2.51x | 2.42x | 2.6x | 2.36x |
| EV / Revenue | 1.53x | 1.79x | 2.14x | 1.82x | 1.92x | 1.79x |
| EV / EBITDA | 13.1x | 37.4x | 21.8x | 16.2x | 14x | 14.3x |
| EV / EBIT | 16x | 56.3x | 24x | 17.7x | 14.9x | 15.2x |
| EV / FCF | -23.5x | -47.2x | 51.9x | 6.92x | 16.7x | 1,719x |
| FCF Yield | -4.25% | -2.12% | 1.93% | 14.5% | 5.99% | 0.06% |
| Dividend per Share 2 | 0.26 | 0.37 | 1 | 1.25 | 2 | 2 |
| Rate of return | 1.05% | 1.38% | 2.47% | 3.4% | 5.23% | 5.73% |
| EPS 2 | 0.26 | 0.37 | 0.84 | 1.25 | 1.59 | 1.54 |
| Distribution rate | 100% | 100% | 119% | 100% | 126% | 130% |
| Net sales 1 | 736.9 | 712.2 | 949.2 | 893.8 | 862.3 | 868.8 |
| EBITDA 1 | 86.03 | 34.04 | 93.06 | 100.3 | 118.7 | 109 |
| EBIT 1 | 70.54 | 22.6 | 84.83 | 92.15 | 111.2 | 102.3 |
| Net income 1 | 17.42 | 21.86 | 49.66 | 73.62 | 93.66 | 90.54 |
| Net Debt 1 | -327.1 | -298.9 | -346.1 | -529.4 | -584.2 | -491.1 |
| Reference price 2 | 24.80 | 26.80 | 40.55 | 36.80 | 38.25 | 34.90 |
| Nbr of stocks (in thousands) | 58,668 | 58,668 | 58,668 | 58,668 | 58,668 | 58,668 |
| Announcement Date | 3/31/21 | 3/28/22 | 3/29/23 | 3/20/24 | 3/13/25 | 3/26/26 |
1TWD in Million2TWD
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
| - | - | - | - | 58.08M | ||
| 60.61x | 7.31x | 25.18x | 0.74% | 135B | ||
| 27.93x | 1.22x | 5.96x | 1.21% | 32.6B | ||
| 14.55x | 0.99x | 5.34x | 3.47% | 14.69B | ||
| 25.03x | 1.18x | 7.5x | 2.91% | 11.81B | ||
| 15.64x | 5.24x | 13.77x | 3.02% | 6.97B | ||
| 24.27x | 0.77x | 7.96x | 1.41% | 5.71B | ||
| 25.86x | 0.61x | 3.11x | -.--% | 3.44B | ||
| Average | 27.70x | 2.48x | 9.83x | 1.82% | 26.28B | |
| Weighted average by Cap. | 47.28x | 5.23x | 18.61x | 1.21% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 4153 Stock
- Valuation DIVA Laboratories, Ltd.
Select your edition
All financial news and data tailored to specific country editions
















